[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Deepak K. Sarpal, M.D.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":66},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100516324","accelerated-transcranial-magnetic-stimulation-for-people-with-schizophrenia-treated-with-clozapine-100516324",false,"NCT06003036","Accelerated Transcranial Magnetic Stimulation for People With Schizophrenia Treated With Clozapine","Accelerated Neuromodulation of Prefrontal Circuitry During Clozapine Treatment","Inclusion Criteria:\n\n1. A current Diagnostic and Statistical Manual of Mental Disorders 5 (DSM 5)-defined diagnosis of schizophrenia or schizoaffective disorder\n2. age 18-50 years\n3. at least 4 months of clozapine treatment\n4. history of at least 2 failed antipsychotic trials\n5. competency and willingness to sign informed consent\n6. A clinically optimized dosage of clozapine, unchanged for at least 1 month, with a minimum of 150 mg\u002Fday\n\nExclusion Criteria:\n\n1. Serious neurologic or medical condition\u002Ftreatment that impacts the brain\n2. a significant risk of suicidal or homicidal behavior\n3. cognitive or language limitations, or any other factor that would preclude subjects providing informed consent\n4. pregnancy or postpartum (\\\u003C6 weeks after delivery or miscarriage)\n5. history of treatment with electroconvulsive therapy\n6. contraindications for magnetic resonance imaging (e.g., a pacemaker)\n7. Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders 5 (DSM 5)-verified moderate or severe substance use disorder, including alcohol use disorder\n8. seizure disorder or prior history of seizures on clozapine\n9. patients taking both bupropion and clozapine\n10. prior issues with intermittent theta burst stimulation\u002Ftranscranial magnetic stimulation administration\n\nConcomitant treatment with serotonin and norepinephrine reuptake inhibitors will be examined on a case-by-case basis.","ALL","18 Years","50 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"NA","In this study, the investigators will examine whether a type of repetitive transcranial magnetic stimulation called accelerated intermittent theta burst stimulation (iTBS) can augment neurocognition in individuals who receive treatment with clozapine. Following a baseline evaluation and magnetic resonance imaging (MRI), participants will undergo a session of iTBS +MRI and session of sham delivery + MRI. The order for these sessions will be blinded and randomized. The investigators predict that accelerated iTBS will enhance neurocognition relative to sham delivery.",[27,28],"Schizophrenia","Schizoaffective Disorder","RECRUITING","2026-04-06",{"date":32,"type":33},"2026-04-13","ACTUAL",{"date":35,"type":33},"2023-12-01",{"date":37,"type":21},"2026-07",{"name":39,"class":40},"Deepak K. Sarpal, M.D.","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":16,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":41},"100559321","phase-4-anticholinergic-deprescription-in-schizophrenia-100559321","NCT06562608","Anticholinergic Deprescription in Schizophrenia","Neural Mechanisms of Anticholinergic Burden in Mid- to Late-Life Schizophrenia Spectrum","Inclusion Criteria:\n\n1. Primary DSM-defined diagnosis of schizophrenia or schizoaffective disorder verified by the Structured Clinical Interview for DSM-5 (SCID).\n2. Prescription of benztropine or trihexyphenidyl for at least 6 months\n3. Age 40-70 years.\n4. ACBS score \\>= 3.\n5. Mild or absent extrapyramidal symptoms (Determined by clinical pharmacists and prescribers).\n6. Competency and willingness to sign informed consent.\n\nInclusion criteria for the healthy control group:\n\n1. Age 40-70 years.\n2. Competency and willingness to sign informed consent.\n\nExclusion Criteria:\n\n1. Serious anticholinergic side-effects (e.g., fever, blurred vision) indicative of a need for immediate removal of anticholinergics,\n2. Serious neurologic or medical condition\u002Ftreatment that impacts the brain and Neurodegenerative conditions such as Parkinson's, dementia, etc.; autoimmune conditions such as Multiple Sclerosis (MS) and lupus; as well as traumatic brain injury (TBI).\n3. Significant risk of suicidal or homicidal behavior.\n4. Cognitive or language limitations, or any other factor that would preclude subjects providing informed consent.\n5. Contraindications for MR imaging (e.g., a pacemaker).\n6. Current SCID-verified substance use disorder will be excluded to avoid the confounding impact of significant substance use comorbidity. Participants with a history of substance use disorder that is in early or full remission will be eligible, to enhance generalizability.\n7. Patients concurrently treated with electroconvulsive therapy will be excluded because of its effects on cognition.\n\nExclusion criteria for Healthy Control (HC) subjects:\n\n1. No history of psychotic illness and no active Axis I disorder as determined by clinical interview using the SCID-NP.\n2. Score greater than 1 on the ACB scale.\n3. MR imaging contraindications.\n4. Neurologic conditions, any serious non-psychiatric disorder that could affect brain functioning, or intellectual disability.\n5. HC with family history of psychosis will be excluded, as such individuals show subtle, but significant cognitive and neurobiological abnormalities.\n6. Individuals currently taking anticholinergic medications for reasons other than SSD.",true,"40 Years","70 Years",{"count":53,"type":21},105,[55],"PHASE4","In this study, the investigators will examine whether a deprescription of unnecessary anticholinergic drugs (benztropine or trihexyphenidyl) can augment quality of life, functioning, and neurocognition in individuals who with schizophrenia. Individuals identified by clinical services who have unneeded prescriptions benztropine or trihexyphenidyl will be eligible for deprescription and study entry. Following a baseline evaluation and magnetic resonance imaging (MRI), participants will will be randomized to either staying on their anticholinergic drugs or undergoing deprescription per routine clinical care, and will undergo follow-up evaluations across 6 months. The investigators predict that reducing and deprescribing these drug, if clinically determined to be unnecessary will will enhance functioning, neurocognition",[27,28],"2026-02-05",{"date":60,"type":33},"2026-02-09",{"date":62,"type":33},"2025-02-01",{"date":64,"type":21},"2029-06-30",{"name":39,"class":40},""]